Podocyturia in Fabry disease: a 10-year follow-up

Bojan Vujkovac, Irena Srebotnik Kirbiš, Tajda Keber, Andreja Cokan Vujkovac, Martin Tretjak and Sandra Radoš Krnel

Department of Internal Medicine, General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia, Faculty of Medicine, Institute of Pathology, University of Ljubljana, Ljubljana, Slovenia and PHARMEC s.p., Ljubljana, Slovenia

Correspondence to: Bojan Vujkovac; E-mail: bojan.vujkovac@guest.arnes.si

ABSTRACT

Background. Fabry disease (FD) is a rare X-linked disorder of sphingolipid metabolism that results in chronic proteinuric nephropathy. Podocytes are one of the most affected renal cells and play an important role in the development and progression of kidney disease. Detached podocytes found in urine (podocyturia) are considered as a non-invasive early marker of kidney injury; however, the dynamics of podocyte loss remains unknown.

Methods. In this 10-year follow-up study, podocyturia and other renal clinical data were evaluated in 39 patients with FD. From 2009 to 2019, podocyturia was assessed in 566 fresh urine samples from 13 male and 26 female FD patients using immunocytochemical detection of podocalyxin.

Results. Podocyturia (number of podocytes per 100 mL of urine) was found in 311/566 (54.9%) of the samples, more frequently (68.9 ± 21.9% versus 50.6 ± 25.9%; P = 0.035) and with higher values (364 ± 286 versus 182 ± 180 number of podocytes per gram of creatinine (Cr) in urine; P = 0.020) in males compared with females. The mean number of assessed samples for each patient was 14.5 (range 3–40) and the frequency of samples with podocyturia ranged from 0% to 100% (median 57%). Podocyturia was already present in 42.9% of patients <20 years of age and in 89.5% of normoalbuminuric patients. Podocyturia correlated with albuminuria (urine albumin:Cr ratio) (r = 0.20, P < 0.001) and a higher incidence and values of podocyturia were observed in patients with lower estimated glomerular filtration rate.

Conclusions. Our data demonstrated that podocyturia is an early clinical event in the development of nephropathy. In addition, we found podocyturia to be a discontinuous event with wide variability.
INTRODUCTION

Fabry disease (FD; Online Mendelian Inheritance in Man 301500) is a rare and progressive X-linked inherited disorder of glycosphingolipid metabolism. As a result of deficient or absent lysosomal α-galactosidase A activity, globotriaosylceramide (Gb3) accumulates in cells, causing structural changes that lead to functional impairment. FD affects hemizygous males and heterozygous females with symptoms that range from very mild to severe. Disease presents with neurological pain, progressive proteinuric kidney disease and cardiomyopathy, as well as cerebrovascular symptoms and premature death. Disease progression can be slowed by early initiation of disease-specific treatment (DST), whether in the form of enzyme replacement therapy or pharmacological chaperone [1–3].

One of the hallmarks of FD is chronic proteinuric nephropathy, which is characterized by deposits of Gb3 and its deacylated derivative lyso-Gb3 in different renal cells and to a large extent in podocytes. Depositions seem to be age-dependent and progressive [4, 5]. Like most proteinuric glomerulopathies, including FD, the first morphologic sign of injury to podocytes is seen as a change in their size and architecture, mainly as reorganization of podocyte foot processes (i.e. foot process effacement) [6–8]. Continuing deposition of sphingolipids leads eventually to detachment and podocytes are lost in the urine (podocyturia). Recently it was shown that mechanisms of podocyte detachment are not just mechanical due to progressive accumulation of sphingolipid deposits, but lyso-Gb3 induces a stress to podocytes characterized by an increase in gene expression of components of the uPAR/αvβ3 integrin system, which plays an important role in podocyte detachment and podocyturia [9, 10]. Since podocytes are highly differentiated cells with a very limited potential of self-renewal, their loss is permanent [6, 11, 12]. Changes in the cytoskeleton of podocytes with foot process effacement and a decreased number or density of podocytes in the glomerular capillary tuft consequently result in alterations of the slit diaphragm, causing proteinuria [6, 8, 13], and in the long-term leads to segmental and global glomerulosclerosis [11, 14, 15], which are both common findings in the later stages of FD nephropathy [5, 16].

Currently albuminuria and proteinuria are commonly used biomarkers to clinically assess kidney injury in FD, but they are not sensitive enough for detecting early kidney injury and therefore it is not possible to initiate treatment at an earlier stage that would lead to better clinical outcomes [17]. Foot process effacement is one of the earliest changes in FD and can therefore be detected before proteinuria and loss of renal function become apparent, but it can only be assessed by invasive kidney biopsy [7]. Recent studies have shown that non-invasive podocyturia may also be a good marker of early kidney injury since podocytes were found in higher numbers in the urine of FD patients compared with healthy subjects even with normoalbuminuria and normoproteinuria [17–19].

Some previous cross-sectional studies have already demonstrated the potential prognostic value of podocyturia...
in FD patients [10, 12, 17–22]. However, the dynamics of podocyte injury and loss remains unknown, therefore we evaluated podocyturia in relation to albuminuria/proteinuria and renal function in a Slovenian population of FD patients in a 10-year follow-up study using standard chromogen immunocytochemistry.

**MATERIALS AND METHODS**

Patients

This study was designed as a longitudinal retrospective observational study and in accordance with the principles of the Helsinki Declaration. The study was approved by the Ethics Committee of the General Hospital Slovenj Gradec (EC 202018) and informed consent was obtained from all subjects. Adult patients with FD who were treated and/or regularly monitored in the National Fabry Center at the General Hospital Slovenj Gradec between the years of 2009 and 2019 were invited to participate in the study. The criteria for inclusion were age > 18 years and confirmed diagnosis of FD in accordance with current guidelines [2]. All patients had the classic form of FD, which was defined according to the literature [23]. Patient mutations are listed in Supplementary data, Table S1.

Laboratory measurements

At each visit, a selection of the following clinical measurements was performed. Serum creatinine (Cr) was measured using isotope dilution mass spectrometry and was reported as micromoles per litre (μmol/L). Renal function was calculated as estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease (CKD) Epidemiology Collaboration equation and expressed in millilitres per minute per body surface area (mL/min/1.73 m²) [24]. GFR slope was calculated in patients where at least three values of serum Cr were available. Albuminuria and proteinuria were expressed as urine albumin/Cr and protein/Cr ratio (UACR and UPCR, respectively) in milligrams per gram (mg/g), which were measured from the second morning urine samples. Definitions for albuminuria and proteinuria and their categorization were used according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [25].

Podocyturia assessment

Podocyturia was assessed using immunocytochemical detection of podocalyxin-positive cells on slides prepared from fresh urine samples with a filter imprint technique where the whole sample was filtered through isopore polycarbonate membrane filters with 5-μm pores (Merck Millipore, Dublin, Ireland; TMTP04700) using the Microfil System (Millipore 3-Place Manifold MIAC3P01, MIHA WGO 72 funnels; Millipore Intertech, Bedford, MA, USA). Cells collected on the filter surface were immediately transferred to a pair of glass slides by the imprint technique and fixed with M-FIX spray fixative (3981; Merck, Darmstadt, Germany). Immunocytochemical staining with monoclonal antibody against podocalyxin (PHM5, Millipore MAB430; Millipore, Bayswater, VIC, Australia) was performed using the automated immunostaining system Ventana Benchmark XT (Roche Diagnostics, Rotkreuz, Switzerland) and the iView detection kit (Roche Diagnostics). The number of podocalyxin-positive cells per slide was counted by an experienced cytologist using a light microscope at magnification 200×. Results were expressed as the number of podocytes per 100 mL of urine (UPodo/100 mL) and per gram of Cr in urine (UPodo/g Cr).

**Statistical analysis**

Data management and descriptive statistics were conducted using Stata version 15.1 (StataCorp, College Station, TX, USA). Quantitative variables were expressed as mean ± SD, except for age, UACR, UPCR and therapy duration, which, being not normally distributed, were expressed as median (range). Intergroup comparisons were analysed by the t-test and the chi-squared test. Bivariate correlation was performed by Spearman’s rank correlation. The significance level was judged at P < 0.05.

**RESULTS**

Patient characteristics

In this longitudinal study, 39 FD patients with at least three podocyturia assessments in the period from 2009 to 2019 were included. Patient characteristics are outlined in Table 1. Individual patient data are available in Supplementary data, Table S1.

At baseline, 19 patients (48.7%) were normoalbuminuric with UACR < 30 mg/g and 22 (56.4%) patients were normoproteinuric with UPCR < 150 mg/g. In both groups, albuminuria and proteinuria were more frequent in males than in females (Table 1). Further details can be found in Supplementary data, Table S2.

Podocyturia in FD patients

Podocyturia was assessed in 566 urine samples of FD patients using immunocytochemical detection of podocalyxin. All samples where podocalyxin-positive cells were detected were considered as positive for podocyturia. Podocalyxin-positive cells exhibited a variable intensity of staining in the cytoplasm (weak, moderate and strong) as well as a variety of morphologies ranging from small to large cells, binucleated cells and cells with foamy cytoplasm (Figure 1), which is concordant with observations of other researchers [17, 26, 27]. Squamous cells, urothelial cells and renal tubular cells present in urinary samples of FD patients were consistently podocalyxin negative (Figure 1).

The mean number of assessed samples for each patient was 14.5 (range 3–40), with more assessments for patients on DST compared with those who were not on therapy (21.3 versus 5.7; P < 0.001) (Table 2).

All podocyturia measurements were expressed as the number of podocytes per 100 mL of urine (UPodo/100 mL) and per gram of creatinine in urine (UPodo/g Cr). There was a good correlation between both methods of expression (r = 0.89, P < 0.001) regardless of sex.

Podocyturia, in general, was higher in males than in females: 19.3 ± 16.0 versus 12.5 ± 9.0 UPodo/100 mL (P = 0.096) and 364 ± 286 versus 182 ± 180 UPodo/g Cr (P = 0.020), respectively (Table 2).

All podocyturia measurements were correlated with UACR (r = 0.20, P < 0.001 and r = 0.17, P < 0.001, respectively) for both sexes (Figure 2). Podocyturia also correlated with UPCR (r = 0.20, P < 0.001 and r = 0.18, P < 0.001, respectively).

Podocyturia frequency and levels

Podocyturia was present in 311/566 (54.9%) samples and significantly more often in males than in females (68.9% versus 50.6%; P = 0.035). There was great variability in the level of podocyturia between samples for individual patients as well as in the frequency and levels of podocyturia between patients. There were only two female patients without podocyturia in all evaluated samples, while podocyturia was found in 11–100% of evaluated samples for
all other patients (Figure 3 and Supplementary data, Table S1). Two females without podocyturia had a relatively small number of evaluated samples (six and three), both were young (ages 23 and 38 years, respectively) and both were clinically asymptomatic and without any laboratory or imaging evidence of kidney disease.

Examples of podocyturia dynamics at the individual patient level are shown in Figure 4.

The frequency and levels of podocyturia for patients up to 40 years old were significantly connected to GFR slope. Patients with podocyturia present in ≥50% samples had a significantly lower GFR slope and higher levels of podocyturia compared with patients with podocyturia present in <50% of samples (Table 3).

Podocyturia in relation to other renal parameters

Podocyturia was present in 42.9% of samples from patients <20 years of age (males 50.0% versus females 40.0%) and was also present in 17 patients (100%) with normoalbuminuria (UACR < 30 mg/g).

Patients with albuminuria had a higher frequency of samples with podocyturia than patients with normoalbuminuria (66.4% versus 46.5%; P = 0.014) while the differences in the levels of podocyturia between these two groups were significant only when expressed as UPodo/g Cr (P = 0.023) (Supplementary data, Table S5). Podocyturia, expressed as UPodo/100 mL and UPodo/g Cr, was related negatively to eGFR (same for both parameters; r = −0.16, P < 0.001) for the entire study population and for females, while for males there was only a tendency to show correlation (P = 0.11 and P = 0.079, respectively). Levels of podocyturia increased with the progress of CKD, reaching highest levels at Stage 3 (Figure 5 and Supplementary data, Table S4).

Podocyturia was higher in the group of Fabry patients receiving DST, but was significant only when expressed as UPodo/g Cr (P = 0.048) (Table 4).

DISCUSSION

This longitudinal study of podocyturia in FD patients confirmed that the loss of podocytes is a variable and irregular phenomenon, as already suggested by Trimarchi [28]. Aside from variability in podocyturia between patients, which can be explained by the well-known heterogeneity of disease severity even between members of the same family [29], we found great variability and irregularity of podocyturia in sequential urinary samples of individual FD patients. Podocyturia was found at some point in almost all of our patients (94.9%), with the exception of two completely asymptomatic young females. Similar to Selvarajah et al. [20], we found podocytes in about half (54.9%) of all patient urine samples. Unfortunately we could not discern any pattern of podocyte loss dynamics, which possibly may be due to unscheduled podocyturia assessments at patient check-ups. Our observation indicates that serial analysis of podocyturia is necessary for estimation of

Table 1. Characteristics of Fabry patients included in the study

| Characteristics                      | All          | Males        | Females      | P-value |
|--------------------------------------|--------------|--------------|--------------|---------|
| Patients, n                          | 39           | 13           | 26           | 0.626   |
| Age at study entry (years), median   | 40 (18–72)   | 40 (19–60)   | 41 (18–72)   | 0.062   |
| Follow-up (months), median           | 84 (21–128)  | 101 (21–128) | 83.5 (21–126) | 0.739   |
| DST, n (%)                           | 22           | 13 (100)     | 9 (34.6)     | <0.001  |
| ACEI/ARB, n (%)                      | 24 (61.5)    | 10 (76.9)    | 14 (53.8)    | 0.163   |
| eGFR (mL/min/1.73 m²), mean ± SD     | 92.9 ± 28.8  | 85.2 ± 39.5  | 96.8 ± 31.6  | 0.024   |
| GFR slope (mL/min/year), mean ± SD   | −1.74 ± 2.41 | −3.28 ± 1.73 | −0.97 ± 2.35 | 0.003   |
| UACR (mg/g), median (range)          | 36.0 (1–6434)| 298.4 (1–1831)| 18.8 (1–6434)| 0.645   |
| UPCR (mg/g), median (range)          | 122.1 (60–6591)| 449.4 (80–2021)| 113.9 (60–6591)| 0.594   |
| Normoalbuminuric, a n (%)            | 19 (48.7)    | 4 (30.8)     | 15 (57.7)    | 0.113   |
| Normoproteinuric, b n (%)            | 22 (56.4)    | 4 (30.8)     | 18 (69.2)    | 0.022   |

aNormoalbuminuric: UACR < 30 mg/g.
bNormoproteinuric: UPCR < 150 mg/g.

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Our study confirmed that podocyturia is an early event and an early sign of kidney injury, as it was detected in almost half of the patients <20 years of age and in 90% of normoalbuminuric patients. The incidence and level of podocyturia were found to increase with the level of albuminuria/proteinuria, which are known as the best predictors of renal disease progression, as their magnitude increases with decreasing renal function [31]. Similarly, our data indicate that the level of podocyturia, as well as the incidence of podocyturia, might have predictive value for the progressive nature of kidney injury. The incidence of podocyturia increased as kidney function deteriorated and was highest in the later stages of kidney disease. However, the values of podocyturia increased with CKD stages, reaching a peak at Stage 3 and declined in later stages (4 and 5), which is concordant with a speculative model of podocyturia proposed by Trimarchi et al. [18]. Lower levels of podocyturia at later stages of CKD could indicate progressive loss of podocytes that eventually leads to the development of podocytopaenia.

Previous studies on the natural progression of Fabry nephropathy have shown that the onset of clinical signs of kidney injury usually appears at ~40 years of age [32, 33]. Our analysis in a subset of FD patients in the age group of up to 40 years of age indeed showed a significant connection between the incidence of podocyturia and renal disease outcome. Patients with a high incidence of podocyturia (>50%) showed greater declines in GFR and eventually higher levels of podocyturia, while no difference was observed for UACR. This finding might have an important application in clinical practice for predicting which patients are at higher risk for disease progression. However, additional confirmation with a greater number of FD patients, counting males and females separately, would be necessary.

In our study, UACR and UPCR were strongly correlated with podocyturia in both sexes, as previously reported by some other authors [17, 21]. An inverse association was also observed between podocyturia and GFR. But correlation coefficients for UACR, UPCR and GFR were very low as a consequence of podocyturia variability. These results indicate that podocyturia is associated with disease progression and severity, although individual podocyturia measurements have very low predictive value regarding albuminuria/proteinuria and GFR.

Similar to other studies [17, 20], we did not observe any associations between DST treatment of FD patients and podocyturia. In contrast to the study of Trimarchi et al. [18], we found an even higher incidence and levels of podocyturia in treated compared with untreated patients. However, the results of this analysis in our group of FD patients are questionable, as treated patients were older and significantly more affected by the disease at the time of study entry. Moreover, sex distribution in both groups was uneven, as all males were treated in contrast to one-third of females. Finally, the majority of our patients (13/22) received DST many years before their first podocyturia assessment, therefore the effect of treatment on podocyturia in those patients could not be assessed. In addition, among nine patients who started with DST later, only one female with mainly heart involvement had at least three assessments before and after the DST initiation. As already stated by Fall et al. [17], objective evaluation of the connection between podocyturia and treatment would require additional

![FIGURE 2: Correlation between podocyturia (UPodo) and albuminuria (UACR) in Fabry patients.](image-url)
FIGURE 3: Frequency of podocyturia in individual Fabry patients included in this study.

FIGURE 4: Dynamics of podocyturia (UPodo/100 mL) and eGFR for one male and one female Fabry patient.

Table 3. Renal parameters for Fabry patients up to 40 years old with high (>50%) and low (<50%) frequency of podocyturia

| Characteristics                  | Podocyturia <50% | Podocyturia ≥50% | P-value |
|----------------------------------|------------------|------------------|---------|
| Patients, n (M, F)               | 10 (3, 7)        | 10 (4, 6)        | 0.639   |
| Age at study entry (years), median (range) | 31.5 (18–40) | 31.0 (18–35) | 0.749   |
| Samples, n                       | 58               | 94               |         |
| Samples with podocyturia, %      | 24.1             | 63.2             | <0.001  |
| UACR (mg/g), median (range)      | 18.2 (4–294)     | 23.2 (1–315)     | 0.721   |
| eGFR (mL/min/1.73 m²), mean ± SD | 110.2 ± 13.1     | 115.0 ± 8.7      | 0.344   |
| GFR slope (mL/min/year), mean ± SD | −0.23 ± 2.36   | −2.22 ± 1.55     | 0.039   |
| DST, n (%)                       | 3 (30.0)         | 3 (30.0)         | 1.000   |
| UPodo/100 mL, mean ± SD          | 5.4 ± 6.4        | 19.8 ± 14.3      | 0.009   |
| UPodo/g Cr, mean ± SD            | 83 ± 128         | 277 ± 247        | 0.041   |

F, female; M, male. Samples (n) correspond to all urine assessments for podocyturia. Mean UPodo/100 mL and UPodo/g Cr values refer to mean podocyturia per patient.
longitudinal studies on younger patients without proteinuria and more consecutive podocyte assessments before treatment initiation followed by regular follow-ups.

The higher incidence and values of podocyturia in males than in females found in this study is concordant with the previously reported observation that males tend to have a higher disease burden than females [1].

The phenomenon of podocyturia is not limited to kidney disease and can be found in anyone without signs of kidney disease [34]. The frequencies and values of podocyturia in healthy individuals are lower than in patients with kidney diseases, and especially in patients with FD [17, 18]. We found podocyturia 7-fold more frequently and with higher values in FD patients than in a control group of 88 healthy individuals (52 females and 36 males, ages 20–80 years). Notably, podocyturia was found in 7 (8%) of these healthy individuals in a range of 1–20 UPodo/100 mL and with an average value of 0 ± 2 UPodo/100 mL [35].

Several studies already demonstrated that assessment of podocyturia could represent a non-invasive tool to detect subclinical kidney injury as well as a biomarker for monitoring progression and effect of treatment in various kidney diseases [6, 36–38]. However, the existing methods to assess podocyturia are not suitable for wide application in clinical settings, as these methods are time-consuming, expensive, laborious and not standardized. Moreover, the best urinary podocyte-specific markers have not yet been firmly established [18, 19, 30, 39]. Podocalyxin and synaptopodin, which were used as a target protein to detect podocyturia in Fabry patients [17, 18, 21, 39, 40], might be affected by the disease processes, as shown by some studies [41–43]. Podocytes with structural changes on podocalyxin or synaptopodin or with their reduced expression might remain undetected. Besides that, several other methodological factors might also affect successful detection of detached podocytes in urine, such as different clones of antibodies detecting specific parts on the podocalyxin or synaptopodin molecule, sample preparation, fixation procedures and detection systems used to demonstrate antibody binding site. In our study, podocalyxin was used as a target molecule to detect podocytes in the urine of Fabry patients, as it is considered the most robust and frequently used podocyte-specific marker [41]; moreover, our in-house validation confirmed effective detection of podocytes using the described method.

In the majority of podocyturia studies, immunofluorescence is used for the detection of different podocyte-specific markers [10, 17, 19, 44–46]. However, immunofluorescence requires a special microscope that is not widely available. Therefore, in this study, immunocytochemical detection of podocalyxin was used to assess podocyturia instead of immunofluorescence. Immunocytochemistry is a standard, well-established and mainly automated ancillary diagnostic method available in practically every cytological and histological laboratory. As slides with immunocytochemical reactions are permanent, the slides can be stored and evaluated repeatedly over many years. Our study showed that immunocytochemistry might facilitate a more affordable and feasible assessment of podocyturia.

In conclusion, our study clearly demonstrated that podocyturia is an early clinical event that is already present in young patients while they were still normoalbuminuric. The higher incidence of podocyturia in younger patients could present a useful biomarker to predict the worst outcomes. Podocyturia is associated with all important renal parameters of disease progression. The presence of high variability in the incidence and quantity of podocyturia requires serial analyses of repeated urine samples to correctly evaluate disease progression. Immunocytochemical detection of podocalyxin is a standardized and widely available method.

### SUPPLEMENTARY DATA

Supplementary data are available at ckj online.

### ACKNOWLEDGEMENTS

Informed consent was obtained from all subjects involved in the study. The study was approved by the Ethics Committee of the General Hospital Slovenj Gradec. The authors would like to thank Kristof Krel for his suggestions and help with statistical analysis. Editorial assistance, in the form of language editing and correction, was provided by XpertScientific Editing and Consulting Services.

### FUNDING

This research received no external funding.
CONFLICT OF INTEREST STATEMENT

B.V. received speaker honoraria and travel support from Sanofi Genzyme, Takeda, Greenovation and Amicus and is a member of the European Fabry Registry Board of Advisors, sponsored by Sanofi Genzyme. I.S.K. received speaker honoraria and travel support from Takeda. A.C.V. and M.T. received speaker honoraria and travel support from Sanofi Genzyme and Takeda. The other authors declare that they have no competing interests. The results presented in this article have not been published previously in whole or part, except in abstract format.

DATA AVAILABILITY STATEMENT

The data underlying this article are available in the article and in its supplementary material.

REFERENCES

1. Germain DP. Fabry disease. Orphanet J Rare Dis 2010; 5: 30
2. Ortiz A, Germain DP, Desnick RJ et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 2018; 123: 416–427
3. Desnick RJ. Fabry disease: α-galactosidase A deficiency. In: Rosenberg R N, Fuscus J M (eds). The Online Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease, Vol. 1, 6th edn. San Diego, CA: Elsevier, 2016, 13
4. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002; 13: S134–S138
5. Najaﬁan B, Svarstad E, Bostad L et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 2011; 79: 663–670
6. Müllner-Deile J, Schiffer M. Podocytes from the diagnostic and therapeutic point of view. Pflugers Arch 2017; 469: 1007–1015
7. Tønndel C, Kanai T, Larsen K K et al. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron 2015; 129: 16–21
8. Becherucci F, Romagnani P. When feet come ﬁrst: early signs of podocyte injury in Fabry nephropathy without proteinuria. Nephron 2015; 129: 3–5
9. Trimarchi H, Ortiz A, Sánchez-Nino MD. Lyso-Gb3 increases αvβ3 integrin gene expression in cultured human podocytes in Fabry nephropathy. J Clin Med 2020; 9: 3659
10. Trimarchi H, Canzonieri R, Schiel A et al. Expression of uPAR in urinary podocytes of patients with Fabry disease. Int J Nephrol 2017; 2017: 1287289
11. Trimarchi H. Podocyturia: what is in a name? J Transl Int Med 2015; 3: 51–56
12. Najaﬁan B, Tønndel C, Svarstad E et al. Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol 2020; 31: 865–875
13. Yu D, Petermann A, Kunter U et al. Urinary podocyte loss is a more speciﬁc marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005; 16: 1733–1741
14. Kriz W, Lemley KV. A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. J Am Soc Nephrol 2015; 26: 258–269
15. Nagata M. Podocyte injury and its consequences. Kidney Int 2016; 89: 1221–1230
16. Fogo AB, Bostad L, Svarstad E et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010; 25: 2168–2177
17. Fall B, Scott CR, Mauer M et al. Urinary podocyte loss is increased in patients with Fabry disease and correlates with clinical severity of Fabry nephropathy. PLoS One 2016; 11: e0168346
18. Trimarchi H, Canzonieri R, Schiel A et al. Podocyturia is signiﬁcantly elevated in untreated vs treated Fabry adult patients. J Nephrol 2016; 29: 791–797
19. Trimarchi H, Canzonieri R, Schiel A et al. Increased urinary CD80 excretion and podocyturia in Fabry disease. J Transl Med 2016; 14: 289
20. Selvarajah M, Nicholls K, Hewitson TD et al. Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and speciﬁc diagnostic technique. Nephrol Dial Transplant 2011; 26: 3195–3202
21. Pereira EM, da Silva AS, Labilloy A et al. Podocyturia in Fabry disease. J Bras Nefrol 2016; 38: 49–53
22. Martineau T, Boutin M, Côté A-M et al. Tandem mass spectrometry analysis of urinary podocalyxin and podocin in the investigation of podocyturia in women with preeclampsia and Fabry disease patients. Clin Chim Acta 2019; 495: 67–75
23. Biegraat M, Arngrı¨mler-Deile J, Schiffer M. Podocytes from the diagnostic and therapeutic point of view. Pflugers Arch 2017; 469: 1007–1015
34. Maestroni S, Maestroni A, Dell’Antonio G et al. Viable podocyturia in healthy individuals: implications for podocytopathies. Am J Kidney Dis 2014; 64: 1003–1005
35. Golob Z, Lapoša A, Pajek J et al. Measurement of urine podocyte concentration in healthy individuals. Ther Apher Dial 2009; 13: a22
36. Garovic VD, Wagner SJ, Turner ST et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007; 196: 320.e1–7
37. Habara P, Marecková H, Malíčková K et al. Novel flow cytometric method for the detection of podocalyxin-positive elements in urine of patients with glomerulonephritides - first promising results. Folia Biol (Praha) 2012; 58: 57–63
38. Imaizumi T, Nakatoki M, Akiyama S et al. Urinary podocalyxin as a biomarker to diagnose membranous nephropathy. PLoS One 2016; 11: e0163507
39. Sanchez-Niño MD, Perez-Gomez MV, Valiño-Rivas L et al. Podocyturia: why it may have added value in rare diseases. Clin Kidney J 2019; 12: 49–52
40. Trimarchi H, Canzonieri R, Muryan A et al. Copious podocyтуria without proteinuria and with normal renal function in a young adult with fabry disease. Case Rep Nephrol 2015; 2015: 257628
41. Skoberne A, Konieczny A, Schiffer M. Glomerular epithelial cells in the urine: what has to be done to make them worthwhile? Am J Physiol Renal Physiol 2009; 296: F230–41
42. Kubiak-Wlekły A, Perkowska-Ptasinska A, Olejniczak P et al. The comparison of the podocyte expression of synaptopodin, CR1 and neprilysin in human glomerulonephritis: could the expression of CR1 be clinically relevant? Int J Biomed Sci 2009; 296: F230–241
43. Trimarchi H, Canzonieri R, Costales-Collaguazo C et al. Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes. Clin Kidney J 2019; 12: 53–60
44. Petermann A, Floege J. Podocyte damage resulting in podocyтуria: a potential diagnostic marker to assess glomerular disease activity. Nephron Clin Pract 2007; 106: c61–c66
45. Hara M, Yamagata K, Tomino Y et al. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia 2012; 55: 2913–2919
46. Hara M, Yanagihara T, Kihara I. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schönlein-Henoch purpura nephritis. Clin J Am Soc Nephrol 2007; 2: 231–238